| __timestamp | Madrigal Pharmaceuticals, Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 6795238 |
| Thursday, January 1, 2015 | 13392000 | 7454247 |
| Friday, January 1, 2016 | 9290000 | 10345862 |
| Sunday, January 1, 2017 | 7672000 | 16984203 |
| Monday, January 1, 2018 | 15293000 | 16187290 |
| Tuesday, January 1, 2019 | 22648000 | 9299233.54 |
| Wednesday, January 1, 2020 | 21864000 | 19232000 |
| Friday, January 1, 2021 | 37318000 | 23611000 |
| Saturday, January 1, 2022 | 48130000 | 26700000 |
| Sunday, January 1, 2023 | 108146000 | 28215000 |
Data in motion
In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Summit Therapeutics Inc. and Madrigal Pharmaceuticals, Inc. over the past decade.
From 2014 to 2023, Madrigal Pharmaceuticals saw a staggering 587% increase in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Summit Therapeutics maintained a more conservative growth, with a 315% increase over the same period.
Madrigal's higher SG&A spending could indicate a robust strategy to capture market share, while Summit's steadier approach suggests a focus on sustainable growth. Investors and stakeholders should consider these trends when evaluating the companies' long-term potential.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?